fbpx
Donate Toggle Menu

Dana Farber Recognizes $1 Million in KCA Research Support

The Dana-Farber Cancer Institute (DFCI) in Boston, Massachusetts recently recognized the Kidney Cancer Association (KCA) for supporting researchers at the institution with over $1 million in funding. KCA’s name was placed on the DFCI’s Benefactors…

Rare & Refractory Kidney Cancer Tumors: NCI Targets Both

This is a guest post by D’Ann George, PhD, Medical Writer. Some kidney cancers are so rare that clinicians don’t know enough about them to determine what treatments should be standard, or even to predict…

Kidney Cancer Highlights from 2024 ASCO GU

We rounded up a few research highlights from the 2024 ASCO Genitourinary Cancers Symposium (ASCO GU), held recently in San Francisco, California. Adjuvant immunotherapy improved survival after nephrectomy and could be new standard of care Researchers are…

Expert Opinion: Key Trials from 2024 ASCO GU

This is a guest post by Dr. Arpita Desai, an oncologist at the University of California San Francisco specializing in genitourinary cancers. She summarized the results and takeaways for patients from key trials presented at…

What Palliative Care Is and Isn’t

This is a guest post by D’Ann George, PhD, Medical Writer. Joel Stern vividly remembers the first time he saw the phrase palliative care in his medical file. At the time, in 2020, Stern had…

KCA-funded research shows how family genetics impact kidney cancer

I’m excited to highlight a new study spearheaded by Dr. Ritesh Kotecha from Memorial Sloan Kettering Cancer Center that describes how renal cell carcinoma (RCC) patients’ genetic ancestry (GA) – which is the information about…

ESMO 2023 Kidney Cancer Highlights

We rounded up a few research highlights from the 2023 Congress of the European Society for Medical Oncology (ESMO), held recently in Madrid, Spain. Two new first-line treatment immunotherapy options Toripalimab is a new immunotherapy infusion, a…

Belzutifan results “practice changing” at ESMO 2023

Three analyses of the LITESPARK trial examining the hypoxia-inducible factor 2a (HIF-2a) belzutifan (Welireg) showed efficacy and benefit for this novel therapy over comparator treatments in advanced clear cell renal cell carcinoma (RCC) as well…

Exercise and Sickle Cell Trait: New research unveils the connection

The KCA recently partnered with two advocacy groups on a blog post examining the relationship between exercise and sickle cell trait. This blog post appears at Sick Cells, a national non-profit advocacy group for sickle…

1 2 3 11